The main role of the optical components of the eye is focusing rays of light on the retina. Situation in which parallel rays are focused properly is known as emmetropia. Various defects caused by the inability of the eye to converge the refracted rays on the retina are known as refractive errors (ametropias). The report covers the features and epidemiology facts of hyperopia, myopia and presbyopia.

This report provides the current prevalent population for refractive errors across 18 Major Markets (USA, Canada, France, Germany, Italy, Spain, UK, Poland, Netherlands, Turkey, Japan, China, South Korea, India, Australia, Brazil, Mexico, Argentina) split by gender and 5-year age cohort. In addition to the current prevalence, the report provides an overview of the risk factors, diagnosis and prognosis of the disease, along with specific variations by geography and ethnicity.

Providing a value-added level of insight from the analysis team at Black Swan, several features of refractive errors patients, as well as the main comorbidities of the covered conditions have been quantified and presented alongside the overall prevalence figures. These sub-populations within the main disease are also included at a country level across the 10-year forecast snapshot.

Main symptoms and co-morbidities of refractive errors include:

  • Eye strain
  • Headaches
  • Glaucoma
  • Cataracts
  • Amblyopia
  • Anisometropia
  • Diabetes mellitus
  • Arterial hypertension

This report is built using data and information sourced from the proprietary Epiomic patient segmentation database. To generate accurate patient population estimates, the Epiomic database utilises a combination of several world-class sources that deliver the most up-to-date information form patient registries, clinical trials and epidemiology studies. All of the sources used to generate the data and analysis have been identified in the report.

Reason to buy

  • Ability to quantify patient populations in global refractive errors market to target the development of future products, pricing strategies and launch plans.
  • Further insight into the prevalence of the subdivided types of refractive errors and identification of patient segments with high potential.
  • Delivery of more accurate information for clinical trials in study sizing and realistic patient recruitment for various countries.
  • Better understanding of the impact of specific co-morbid conditions on the prevalent population of refractive errors patients.
  • Identification of refractive errors patient sub-populations that require treatment.
  • Better understanding of the specific markets that have the largest number of refractive errors patients.